Cao Sean Wuxiong 4

What Happened
Cao Sean Wuxiong, Chief Business Development Officer and Director of NovaBridge Biosciences (NBP), received two restricted stock unit (RSU) awards on 2026-06-22 totaling 362,570 RSUs (181,280 and 181,290). The awards are recorded at $0.00 (no purchase price) and are derivative awards that represent a contingent right to receive American Depositary Shares (ADSs) if and when they vest.

Key Details

• Transaction date: 2026-06-22; Form filed: 2026-06-24 (appears timely).
• Awards: 181,280 RSUs and 181,290 RSUs, total 362,570 RSUs (each RSU = 1 ADS per footnote). Reported acquisition price: $0.00.
• Vesting (footnote F3): RSUs vest over four years — 1/4 vests on September 3, 2026, with the remainder vesting ratably over the following 12 quarters on the third day of every third month.
• ADS/ordinary share conversion (footnote F4): 10 ADSs = 23 ordinary shares. The 362,570 ADSs would correspond to ~833,911 ordinary shares if converted (approx.).
• Shares owned after transaction: not specified in the provided filing.
• Note: Footnote F1 clarifies each RSU equals a contingent right to one ADS. Footnote F5 referenced in the filing pertains to a separate option award tied to an $8.00 ADS trigger and does not affect these RSU grants.

Context
RSU grants are compensation awards, not open-market purchases or sales — they do not by themselves signal insider buying intent because no cash was spent and shares are issued only as they vest. For investors, the key takeaways are the size of the grant and the vesting schedule (which creates future potential dilution as units convert to ADSs/ordinary shares). If you want an approximate dollar value, compare the number of ADSs to NovaBridge’s ADS market price on or near the grant date.